Vildagliptin dihydrate

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2133364-01-7

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品名称

维格列汀二水合物
LAF237 dihydrate
NVP-LAF 237 dihydrate

产品介绍

Vildagliptin dihydrate (LAF237 dihydrate) 是一种有效且稳定的选择性二肽基肽酶IV (DPP-IV) 抑制剂，在人 Caco-2 细胞中抑制 DPP-IV 的IC₅₀为 3.5 nM。Vildagliptin dihydrate 具有出色的口服生物利用度和有效的降血糖活性。

生物活性

Vildagliptin dihydrate (LAF237 dihydrate) is a potent, stable, selectivedipeptidyl peptidaseIV (DPP-IV) inhibitor with anIC₅₀of 3.5 nM in human Caco-2 cells. Vildagliptin dihydrate possesses excellent oral bioavailability and potent antihyperglycemic activity^[1].

IC₅₀& Target

IC50: 3.5 nM (DPP-IV, in human Caco-2 cells)^[1]

体外研究
(In Vitro)

Vildagliptin promotes beta cell survival by inhibiting cell apoptosis. Vildagliptin also promotes cell proliferation^[2].

体内研究
(In Vivo)

Vildagliptin (35 mg/kg; once daily by oral gavage) increases plasma active GLP-1 levels in islets of db/db mice^[2].
Vildagliptin (10 μmol/kg; orally) significantly decreases glucose excursions and stimulate insulin secretion in obese male Zucker rats^[1].

Animal Model:	Male db/db mice (BKS) and wildtype mice^[2]
Dosage:	35 mg/kg
Administration:	Oral gavage; once daily; for 6 weeks
Result:	Increased plasma active GLP-1 levels (22.63±1.19 vs. 11.69±0.44).

Animal Model:	Obese male Zucker rats^[1]
Dosage:	10 μmol/kg (Pharmacokinetic Analysis)
Administration:	Orally
Result:	Significantly decreased glucose excursions and stimulate insulin secretion.

Clinical Trial

分子量

339.43

Formula

C₁₇H₂₉N₃O₄

CAS 号

2133364-01-7

中文名称

维达列汀二水合物；维格列汀二水合物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.